Joerg Striessnig

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6896336/joerg-striessnig-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68 180 15,946 123 h-index g-index citations papers 6.6 6.39 17,623 203 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
180	Calcium current modulation by the 🛘 subunit depends on alternative splicing of CaV1.1 <i>Journal of General Physiology</i> , 2022 , 154,	3.4	2
179	Ca2+ Channel Blockers 2021 , 375-383		1
178	Novel CACNA1A Variant p.Cys256Phe Disrupts Disulfide Bonds and Causes Spinocerebellar Ataxia. <i>Movement Disorders</i> , 2021 ,	7	1
177	Stabilization of negative activation voltages of Cav1.3 L-Type Ca-channels by alternative splicing. <i>Channels</i> , 2021 , 15, 38-52	3	4
176	Voltage-Gated Ca-Channel 🛭-Subunit Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies. <i>Frontiers in Synaptic Neuroscience</i> , 2021 , 13, 634760	3.5	16
175	Separation of the Ca 1.2-Ca 1.3 calcium channel duo prevents type 2 allergic airway inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 ,	9.3	1
174	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels. <i>British Journal of Pharmacology</i> , 2021 , 178 Suppl 1, S157-S245	8.6	21
173	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. <i>British Journal of Pharmacology</i> , 2021 , 178 Suppl 1, S1-S26	8.6	20
172	De novo CACNA1D Ca channelopathies: clinical phenotypes and molecular mechanism. <i>Pflugers Archiv European Journal of Physiology</i> , 2020 , 472, 755-773	4.6	16
171	Biophysical classification of a de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder. <i>Molecular Autism</i> , 2020 , 11, 4	6.5	21
170	RBP2 stabilizes slow Cav1.3 Ca channel inactivation properties of cochlear inner hair cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2020 , 472, 3-25	4.6	7
169	Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson's disease. <i>Nature Communications</i> , 2019 , 10, 5094	17.4	31
168	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. <i>British Journal of Pharmacology</i> , 2019 , 176 Suppl 1, S142-S228	8.6	200
167	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. <i>British Journal of Pharmacology</i> , 2019 , 176 Suppl 1, S1-S20	8.6	218
166	Voltage-gated calcium channels (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019 , 2019,	1.7	2
165	The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2019 , 59, 263-289	17.9	41
164	Gating defects of disease-causing de novo mutations in Ca1.3 Ca channels. <i>Channels</i> , 2018 , 12, 388-402	3	17

163	Getting a handle on Ca2.2 (N-type) voltage-gated Ca channels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 12848-12850	11.5	1
162	Loss of El Calcium Channel Subunit Function Increases the Susceptibility for Diabetes. <i>Diabetes</i> , 2017 , 66, 897-907	0.9	21
161	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy. <i>Human Molecular Genetics</i> , 2017 , 26, 2923-2932	5.6	58
160	Lower Affinity of Isradipine for L-Type Ca Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2017 , 37, 67	61-677	7 ⁴⁷
159	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Voltage-gated ion channels. <i>British Journal of Pharmacology</i> , 2017 , 174 Suppl 1, S160-S194	8.6	166
158	Mechanisms Responsible for Pore Currents in Ca Calcium Channel Voltage-Sensing Domains. <i>Biophysical Journal</i> , 2017 , 113, 1485-1495	2.9	13
157	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. <i>British Journal of Pharmacology</i> , 2017 , 174 Suppl 1, S1-S16	8.6	231
156	Ca1.3 L-type Ca channel contributes to the heartbeat by generating a dihydropyridine-sensitive persistent Na current. <i>Scientific Reports</i> , 2017 , 7, 7869	4.9	17
155	Aldosterone-Producing Adenomas: Histopathology-Genotype Correlation and Identification of a Novel Mutation. <i>Hypertension</i> , 2017 , 70, 129-136	8.5	29
154	Splice variants of the Ca1.3 L-type calcium channel regulate dendritic spine morphology. <i>Scientific Reports</i> , 2016 , 6, 34528	4.9	30
153	Ca 1.3 (CACNA1D) L-type Ca channel dysfunction in CNS disorders. <i>Journal of Physiology</i> , 2016 , 594, 58	33 3 .5 ₉ 84	938
152	L-type calcium channels as drug targets in CNS disorders. <i>Channels</i> , 2016 , 10, 7-13	3	54
151	G protein-gated IKACh channels as therapeutic targets for treatment of sick sinus syndrome and heart block. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E932-41	11.5	27
150	L-type Cav1.3 channels regulate ryanodine receptor-dependent Ca2+ release during sino-atrial node pacemaker activity. <i>Cardiovascular Research</i> , 2016 , 109, 451-61	9.9	53
149	CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type calcium channels. <i>Biological Psychiatry</i> , 2015 , 77, 816-22	7.9	104
148	The L-type calcium channel Cav1.3 is required for proper hippocampal neurogenesis and cognitive functions. <i>Cell Calcium</i> , 2015 , 58, 606-16	4	40
147	The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. <i>Pharmacological Reviews</i> , 2015 , 67, 821-70	22.5	562
146	CaV1.2 and CaV1.3 channel hyperactivation in mouse islet [] cells exposed to type 1 diabetic serum. <i>Cellular and Molecular Life Sciences</i> , 2015 , 72, 1197-207	10.3	13

145	The Concise Guide to PHARMACOLOGY 2015/16: Overview. <i>British Journal of Pharmacology</i> , 2015 , 172, 5729-43	8.6	207
144	Compensatory T-type Ca2+ channel activity alters D2-autoreceptor responses of Substantia nigra dopamine neurons from Cav1.3 L-type Ca2+ channel KO mice. <i>Scientific Reports</i> , 2015 , 5, 13688	4.9	31
143	Cell-type-specific tuning of Cav1.3 Ca(2+)-channels by a C-terminal automodulatory domain. <i>Frontiers in Cellular Neuroscience</i> , 2015 , 9, 309	6.1	32
142	Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?. <i>Current Molecular Pharmacology</i> , 2015 , 8, 110-22	3.7	78
141	A Polybasic Plasma Membrane Binding Motif in the I-II Linker Stabilizes Voltage-gated CaV1.2 Calcium Channel Function. <i>Journal of Biological Chemistry</i> , 2015 , 290, 21086-21100	5.4	21
140	Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. <i>Brain</i> , 2014 , 137, 2287-302	11.2	87
139	C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type Ca(2+) channels. <i>Biophysical Journal</i> , 2014 , 106, 1467-75	2.9	27
138	Cav1.2 and Cav1.3 L-type calcium channels regulate dopaminergic firing activity in the mouse ventral tegmental area. <i>Journal of Neurophysiology</i> , 2014 , 112, 1119-30	3.2	49
137	Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators. <i>Nature Communications</i> , 2014 , 5, 3897	17.4	41
136	L-type Ca channels in heart and brain. <i>Environmental Sciences Europe</i> , 2014 , 3, 15-38	5	132
135	Generation of a neuro-specific microarray reveals novel differentially expressed noncoding RNAs in mouse models for neurodegenerative diseases. <i>Rna</i> , 2014 , 20, 1929-43	5.8	21
134	Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. <i>Nature Genetics</i> , 2013 , 45, 1055-60	36.3	353
133	Lonely but diverse: Cav1.3 L-type Ca(2+) channels in cochlear inner hair cells. <i>Channels</i> , 2013 , 7, 133-4	3	3
132	Distinct localization and modulation of Cav1.2 and Cav1.3 L-type Ca2+ channels in mouse sinoatrial node. <i>Journal of Physiology</i> , 2012 , 590, 6327-42	3.9	39
131	Prevalence of hypovitaminosis D and folate deficiency in healthy young female Austrian students in a health care profession. <i>European Journal of Nutrition</i> , 2012 , 51, 1021-31	5.2	7
130	Repertoire of high voltage-activated Ca2+ channels in the lateral superior olive: functional analysis in wild-type, Ca(v)1.3(-/-), and Ca(v)1.2DHP(-/-) mice. <i>Journal of Neurophysiology</i> , 2012 , 108, 365-79	3.2	17
129	Ca(V)1.3-driven SK channel activation regulates pacemaking and spike frequency adaptation in mouse chromaffin cells. <i>Journal of Neuroscience</i> , 2012 , 32, 16345-59	6.6	46
128	Structural determinants of CaV1.3 L-type calcium channel gating. <i>Channels</i> , 2012 , 6, 197-205	3	23

127	Cav 1.3 L-type Ca (2+) channels mediate long-term adaptation in dopamine D2L-mediated GluA1 trafficking in the dorsal striatum following cocaine exposure. <i>Channels</i> , 2012 , 6, 11-7	3	14
126	Cav1.3 L-Type Calcium Channels-Mediated Ryanodine Receptor Dependent Calcium Release Controls Heart Rate. <i>Biophysical Journal</i> , 2011 , 100, 567a	2.9	4
125	Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. <i>Nature Neuroscience</i> , 2011 , 14, 77-84	25.5	208
124	Structural determinants of CaV1.3 L-type calcium channel gating. <i>BMC Pharmacology</i> , 2011 , 11, A11		78
123	Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011 , 4, 733-4	. 2 6.4	44
122	Functional properties of a newly identified C-terminal splice variant of Cav1.3 L-type Ca2+ channels. Journal of Biological Chemistry, 2011 , 286, 42736-42748	5.4	97
121	Cav1.3 calcium channels are required for normal development of the auditory brainstem. <i>Journal of Neuroscience</i> , 2011 , 31, 8280-94	6.6	70
120	Cav1.2 L-type Call+ channels mediate cocaine-induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Ca(v)1.3 channels. <i>Journal of Neuroscience</i> , 2011 , 31, 13562-75	6.6	69
119	Pacemaker activity and ionic currents in mouse atrioventricular node cells. <i>Channels</i> , 2011 , 5, 241-50	3	29
118	Functional roles of Ca(v)1.3, Ca(v)3.1 and HCN channels in automaticity of mouse atrioventricular cells: insights into the atrioventricular pacemaker mechanism. <i>Channels</i> , 2011 , 5, 251-61	3	70
117	Are Ca(v)1.3 pacemaker channels in chromaffin cells? Possible bias from resting cell conditions and DHP blockers usage. <i>Channels</i> , 2011 , 5, 219-24	3	25
116	Molecular switch from L-type Ca v 1.3 to Ca v 1.2 Ca2+ channel signaling underlies long-term psychostimulant-induced behavioral and molecular plasticity. <i>Journal of Neuroscience</i> , 2010 , 30, 17051-0	52.6	44
115	Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. <i>Journal of Neuroscience</i> , 2010 , 30, 491-504	6.6	129
114	Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14950-7	11.5	219
113	Pacemaker Cells of the Atrioventricular Node are CaV1.3 Dependent Oscillators. <i>Biophysical Journal</i> , 2010 , 98, 339a	2.9	2
112	Modulation of Cav1.3 Ca2+ channel gating by Rab3 interacting molecule. <i>Molecular and Cellular Neurosciences</i> , 2010 , 44, 246-59	4.8	48
111	CaV1.3 L-type Ca2+ channels modulate depression-like behaviour in mice independent of deaf phenotype. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 499-513	5.8	8o
110	Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2+ channels. <i>Pflugers Archiv European Journal of Physiology</i> , 2010 , 460, 361-74	4.6	98

109	Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. <i>Molecular Pharmacology</i> , 2009 , 75, 407-14	4.3	158
108	Use-dependent block of voltage-gated Cav2.1 Ca2+ channels by petasins and eudesmol isomers. Journal of Pharmacology and Experimental Therapeutics, 2009 , 330, 220-6	4.7	18
107	An oily competition: role of beta subunit palmitoylation for Ca2+ channel modulation by fatty acids. Journal of General Physiology, 2009 , 134, 363-7	3.4	4
106	Activity and calcium regulate nuclear targeting of the calcium channel beta4b subunit in nerve and muscle cells. <i>Channels</i> , 2009 , 3, 343-55	3	36
105	Anthracene based compounds as new L-type Ca2+ channel blockers: design, synthesis, and full biological profile. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 1259-62	8.3	11
104	A destructive interaction mechanism accounts for dominant-negative effects of misfolded mutants of voltage-gated calcium channels. <i>Journal of Neuroscience</i> , 2008 , 28, 4501-11	6.6	65
103	Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. <i>Channels</i> , 2008 , 2, 233-51	3	76
102	Functional properties and modulation of extracellular epitope-tagged Ca(V)2.1 voltage-gated calcium channels. <i>Channels</i> , 2008 , 2, 461-73	3	22
101	Role of L-type Ca2+ channel isoforms in the extinction of conditioned fear. <i>Learning and Memory</i> , 2008 , 15, 378-86	2.8	29
100	Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3628-33	11.5	304
99	Modulation of voltage- and Ca2+-dependent gating of CaV1.3 L-type calcium channels by alternative splicing of a C-terminal regulatory domain. <i>Journal of Biological Chemistry</i> , 2008 , 283, 20733	-44	105
98	Voltage-dependent calcium channel CaV1.3 subunits regulate the light peak of the electroretinogram. <i>Journal of Neurophysiology</i> , 2007 , 97, 3731-5	3.2	53
97	C-terminal tailoring of L-type calcium channel function. <i>Journal of Physiology</i> , 2007 , 585, 643-4	3.9	13
96	Ca(v)1.3 channels produce persistent calcium sparklets, but Ca(v)1.2 channels are responsible for sparklets in mouse arterial smooth muscle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H1359-70	5.2	43
95	The role of physiological afferent nerve activity during in vivo maturation of the calyx of Held synapse. <i>Journal of Neuroscience</i> , 2007 , 27, 1725-37	6.6	53
94	Molecular nature of anomalous L-type calcium channels in mouse cerebellar granule cells. <i>Journal of Neuroscience</i> , 2007 , 27, 3855-63	6.6	27
93	Role of Cav1.2 L-type Ca2+ channels in vascular tone: effects of nifedipine and Mg2+. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 292, H415-25	5.2	52
92	Voltage-dependent calcium channels and cardiac pacemaker activity: from ionic currents to genes. <i>Progress in Biophysics and Molecular Biology</i> , 2006 , 90, 38-63	4.7	83

(2003-2006)

Role of voltage-gated L-type Ca2+ channel isoforms for brain function. <i>Biochemical Society Transactions</i> , 2006 , 34, 903-9	5.1	142
Brain activation pattern induced by stimulation of L-type Ca2+-channels: contribution of Ca(V)1.3 and Ca(V)1.2 isoforms. <i>Neuroscience</i> , 2006 , 139, 1005-15	3.9	49
Effects of congenital stationary night blindness type 2 mutations R508Q and L1364H on Cav1.4 L-type Ca2+ channel function and expression. <i>Journal of Neurochemistry</i> , 2006 , 96, 1648-58	6	28
C-terminal modulator controls Ca2+-dependent gating of Ca(v)1.4 L-type Ca2+ channels. <i>Nature Neuroscience</i> , 2006 , 9, 1108-16	25.5	118
Pathophysiology of migraine headache: Insight from pharmacology and genetics. <i>Drug Discovery Today Disease Mechanisms</i> , 2005 , 2, 453-462		4
International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. <i>Pharmacological Reviews</i> , 2005 , 57, 411-25	22.5	970
A CACNA1F mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 7553-8	11.5	120
Congenital stationary night blindness type 2 mutations S229P, G369D, L1068P, and W1440X alter channel gating or functional expression of Ca(v)1.4 L-type Ca2+ channels. <i>Journal of Neuroscience</i> , 2005 , 25, 252-9	6.6	73
The Molecular Basis of Ca2+ Antagonist Drug Action-Recent Developments 2005 , 262-280		
Exploring the Function and Pharmacotherapeutic of Potential Voltage-Gated Ca2+ Channels with Gene-Knockout Models 2005 , 346-372		1
Familial hemiplegic migraine type 1 mutations K1336E, W1684R, and V1696I alter Cav2.1 Ca2+ channel gating: evidence for beta-subunit isoform-specific effects. <i>Journal of Biological Chemistry</i> , 2004 , 279, 51844-50	5.4	57
Opposite effects of a single IIIS5 mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels. <i>Journal of Biological Chemistry</i> , 2004 , 279, 55211-7	5.4	8
Disturbed atrio-ventricular conduction and normal contractile function in isolated hearts from Cav1.3-knockout mice. <i>Naunyn-Schmiedebergls Archives of Pharmacology</i> , 2004 , 369, 554-62	3.4	34
L-type Ca2+ channels in Ca2+ channelopathies. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 322, 1341-6	3.4	45
The monoclonal antibody mAB 1A binds to the excitationcontraction coupling domain in the II-III loop of the skeletal muscle calcium channel alpha(1S) subunit. <i>Archives of Biochemistry and Biophysics</i> , 2004 , 427, 91-100	4.1	17
Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1430-9	15.9	144
Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 5543-8	11.5	362
CaV1.3 channels are essential for development and presynaptic activity of cochlear inner hair cells. Journal of Neuroscience, 2003 , 23, 10832-40	6.6	304
	Brain activation pattern induced by stimulation of L-type Ca2+-channels: contribution of Ca(V)1.3 and Ca(V)1.2 Isoforms. Neuroscience, 2006, 139, 1005-15 Effects of congenital stationary night blindness type 2 mutations R508Q and L1364H on Cav1.4 L-type Ca2+ channel function and expression. Journal of Neurochemistry, 2006, 96, 1648-58 C-terminal modulator controls Ca2+-dependent gating of Ca(V)1.4 L-type Ca2+ channels. Nature Neuroscience, 2006, 9, 1108-16 Pathophysiology of migraine headache: Insight from pharmacology and genetics. Drug Discovery Today Disease Mechanisms, 2005, 2, 453-462 International Union of Pharmacology, XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacological Reviews, 2005, 57, 411-25 A CACNA1F mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7553-8 Congenital stationary night blindness type 2 mutations S229P, G369D, L1068P, and W1440X alter channel gating or functional expression of Ca(V)1.4 L-type Ca2+ channels. Journal of Neuroscience, 2005, 25, 252-9 The Molecular Basis of Ca2+ Antagonist Drug Action-Recent Developments 2005, 262-280 Exploring the Function and Pharmacotherapeutic of Potential Voltage-Gated Ca2+ Channels with Gene-Knockout Models 2005, 346-372 Familial hemiplegic migraine type 1 mutations K1336E, W1684R, and V1696i alter Cav2.1 Ca2+ channel gating: evidence for beta-subunit isoform-specific effects. Journal of Biological Chemistry, 2004, 279, 51844-50 Opposite effects of a single IISS mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels. Journal of Biological Chemistry, 2004, 279, 51844-50 The monoclonal antibody mAB 1A binds to the excitation-contraction coupling domain in the II-III loop of the skeletal muscle calcium channel alpha(1S) subunit. Archives of Biochemistry and Biophysics, 2004, 427, 91-100 Soform-specific	Brain activation pattern induced by stimulation of L-type Ca2+-channels: contribution of Ca(V)1.3 and Ca(V)1.2 isoforms. Neuroscience, 2006, 139, 1005-15 Effects of congenital stationary night blindness type 2 mutations R508Q and L1364H on Cav1.4 L-type Ca2+ channel function and expression. Journal of Neurochemistry, 2006, 96, 1648-58 C-terminal modulator controls Ca2+-dependent gating of Ca(V)1.4 L-type Ca2+ channels. Nature Neuroscience, 2006, 9, 1108-16 Pathophysiology of migraine headache: Insight from pharmacology and genetics. Drug Discovery Today Disease Mechanisms, 2005, 2, 453-462 International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacological Reviews, 2005, 57, 411-25 A CACNATF mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7553-8 Congenital stationary night blindness type 2 mutations S229P, G369D, L1068P, and W1440X alter channel gating or functional expression of Ca(V)1.4 L-type Ca2+ channels. Journal of Neuroscience, 2005, 25, 252-9 The Molecular Basis of Ca2+ Antagonist Drug Action-Recent Developments 2005, 262-280 Exploring the Function and Pharmacotherapeutic of Potential Voltage-Gated Ca2+ Channels with Gene-Knockout Models 2005, 346-372 Familial hemiplegic migraine type 1 mutations K1336E, W1684R, and V1696I alter Cav2.1 Ca2+ channel gating: evidence for beta-subunit isoform-specific effects. Journal of Biological Chemistry, 2004, 279, 51844-50 Opposite effects of a single IIISS mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels. Journal of Biological Chemistry, 2004, 279, 55211-7 Disturbed atrio-ventricular conduction and normal contractile function in isolated hearts from Cav1.3-knockout mice. Naunyn-Schmiedebergis Archives of Pharmacology, 2004, 369, 554-62 1-type Ca2+ channels in Ca2+ channels on the excitat

73	Cav1.4alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation. <i>Journal of Neuroscience</i> , 2003 , 23, 6041-9	6.6	113
72	Cav1.3 (alpha1D) Ca2+ currents in neonatal outer hair cells of mice. <i>Journal of Physiology</i> , 2003 , 553, 747-58	3.9	103
71	Neurobiology of migraine. <i>Nature Reviews Neuroscience</i> , 2003 , 4, 386-98	13.5	433
70	International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. <i>Pharmacological Reviews</i> , 2003 , 55, 579-81	22.5	201
69	Visualization of the domain structure of an L-type Ca2+ channel using electron cryo-microscopy. Journal of Molecular Biology, 2003 , 332, 171-82	6.5	93
68	Neurological phenotype and synaptic function in mice lacking the CaV1.3 alpha subunit of neuronal L-type voltage-dependent Ca2+ channels. <i>Neuroscience</i> , 2003 , 120, 435-42	3.9	65
67	Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade. <i>Journal of Neurophysiology</i> , 2002 , 87, 2490-504	4 ^{3.2}	78
66	Familial hemiplegic migraine mutations increase Ca(2+) influx through single human CaV2.1 channels and decrease maximal CaV2.1 current density in neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 13284-9	11.5	209
65	Functional consequences of P/Q-type Ca2+ channel Cav2.1 missense mutations associated with episodic ataxia type 2 and progressive ataxia. <i>Journal of Biological Chemistry</i> , 2002 , 277, 6960-6	5.4	82
64	Calcium channels in mouse hair cells: function, properties and pharmacology. <i>Advances in Oto-Rhino-Laryngology</i> , 2002 , 59, 35-41	1.7	24
63	A mutation in the beta interaction domain of the Ca(2+) channel alpha(1C) subunit reduces the affinity of the (+)-[(3)H]isradipine binding site. <i>FEBS Letters</i> , 2002 , 524, 188-92	3.8	4
62	Mechanism of dihydropyridine interaction with critical binding residues of L-type Ca2+ channel alpha 1 subunits. <i>Journal of Biological Chemistry</i> , 2001 , 276, 12730-5	5.4	37
61	alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. <i>Journal of Biological Chemistry</i> , 2001 , 276, 22100-6	5.4	356
60	Down-regulation of L-type calcium channels in inflamed circular smooth muscle cells of the canine colon. <i>Gastroenterology</i> , 2001 , 120, 480-9	13.3	102
59	Fast exocytosis with few Ca(2+) channels in insulin-secreting mouse pancreatic B cells. <i>Biophysical Journal</i> , 2001 , 81, 3308-23	2.9	207
58	Targeting voltage-gated Ca2+ channels. <i>Lancet, The</i> , 2001 , 357, 1294	40	9
57	Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain. <i>Biochemical Journal</i> , 2000 , 347, 829	3.8	27
56	Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain. <i>Biochemical Journal</i> , 2000 , 347, 829-836	3.8	60

55	High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. <i>British Journal of Pharmacology</i> , 2000 , 130, 669-77	8.6	50
54	Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. <i>Cell</i> , 2000 , 102, 89-97	56.2	703
53	Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. <i>Journal of Biological Chemistry</i> , 2000 , 275, 39193-9	5.4	207
52	Three new familial hemiplegic migraine mutants affect P/Q-type Ca(2+) channel kinetics. <i>Journal of Biological Chemistry</i> , 2000 , 275, 9239-43	5.4	109
51	beta subunit heterogeneity of L-type Ca(2+) channels in smooth muscle tissues. <i>FEBS Letters</i> , 2000 , 467, 65-9	3.8	28
50	Subcellular localization of chromogranins, calcium channels, amine carriers, and proteins of the exocytotic machinery in bovine splenic nerve. <i>Journal of Neurochemistry</i> , 1999 , 72, 1110-6	6	34
49	Pharmacology, structure and function of cardiac L-type Ca(2+) channels. <i>Cellular Physiology and Biochemistry</i> , 1999 , 9, 242-69	3.9	167
48	Current modulation and membrane targeting of the calcium channel alpha1C subunit are independent functions of the beta subunit. <i>Journal of Physiology</i> , 1999 , 517 (Pt 2), 353-68	3.9	79
47	Molecular basis of drug interaction with L-type Ca2+ channels. <i>Journal of Bioenergetics and Biomembranes</i> , 1998 , 30, 319-34	3.7	46
46	Structural basis of drug binding to L Ca2+ channels. <i>Trends in Pharmacological Sciences</i> , 1998 , 19, 108-15	5 1 3.2	231
45	Familial hemiplegic migraine mutations change alpha1A Ca2+ channel kinetics. <i>Journal of Biological Chemistry</i> , 1998 , 273, 5586-90	5.4	157
44	Molecular mechanism of diltiazem interaction with L-type Ca2+ channels. <i>Journal of Biological Chemistry</i> , 1998 , 273, 27205-12	5.4	42
43	Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha1A subunit. Role of L-type Met1188. <i>Journal of Biological Chemistry</i> , 1997 , 272, 27686-93	5.4	65
42	Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 13323-8	11.5	72
41	L-type calcium channels: binding domains for dihydropyridines and benzothiazepines are located in close proximity to each other. <i>Biochemistry</i> , 1997 , 36, 3625-31	3.2	24
40	Analysis of membrane protein self-association in lipid systems by fluorescence particle counting: application to the dihydropyridine receptor. <i>Biochemistry</i> , 1997 , 36, 4497-504	3.2	9
39	The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. <i>Trends in Pharmacological Sciences</i> , 1997 , 18, 67-70	13.2	82
38	Beta subunit heterogeneity in neuronal L-type Ca2+ channels. <i>Journal of Biological Chemistry</i> , 1997 , 272, 13877-82	5.4	96

37	Identification of PK-A phosphorylation sites in the carboxyl terminus of L-type calcium channel alpha 1 subunits. <i>Biochemistry</i> , 1996 , 35, 9400-6	3.2	84
36	Block of P/Q-type calcium channels by therapeutic concentrations of aminoglycoside antibiotics. <i>Biochemistry</i> , 1996 , 35, 14659-64	3.2	49
35	Extra- and intracellular action of quaternary devapamil on muscle L-type Ca(2+)-channels. <i>British Journal of Pharmacology</i> , 1996 , 119, 1197-202	8.6	14
34	Transfer of 1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels. <i>Neuron</i> , 1996 , 16, 207-18	13.9	137
33	Purification, molecular cloning, and expression of the mammalian sigma1-binding site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 8072-7	11.5	762
32	Transfer of L-type calcium channel IVS6 segment increases phenylalkylamine sensitivity of alpha1A. <i>Journal of Biological Chemistry</i> , 1996 , 271, 11745-9	5.4	46
31	Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels. <i>Journal of Biological Chemistry</i> , 1996 , 271, 24471-5	5.4	68
30	Chloride and potassium conductances of mouse pancreatic zymogen granules are inversely regulated by a approximately 80-kDa mdr1a gene product. <i>Journal of Biological Chemistry</i> , 1996 , 271, 3300-5	5.4	25
29	Identification of benz(othi)azepine-binding regions within L-type calcium channel alpha1 subunits. <i>Journal of Biological Chemistry</i> , 1996 , 271, 20113-8	5.4	33
28	Phenylalkylamine Ca2+ antagonist binding protein. Molecular cloning, tissue distribution, and heterologous expression. <i>Journal of Biological Chemistry</i> , 1995 , 270, 7551-7	5.4	65
27	Benzothiazepine binding domain of purified L-type calcium channels: direct labeling using a novel fluorescent diltiazem analogue. <i>Biochemistry</i> , 1995 , 34, 3461-9	3.2	12
26	Coordination of Ca2+ by the pore region glutamates is essential for high-affinity dihydropyridine binding to the cardiac Ca2+ channel alpha 1 subunit. <i>Biochemistry</i> , 1995 , 34, 9350-5	3.2	46
25	Calcium channels: the beta-subunit increases the affinity of dihydropyridine and Ca2+ binding sites of the alpha 1-subunit. <i>FEBS Letters</i> , 1994 , 352, 141-5	3.8	52
24	Insect calcium channels. Molecular cloning of an alpha 1-subunit from housefly (Musca domestica) muscle. <i>FEBS Letters</i> , 1994 , 339, 189-94	3.8	34
23	Complex molecular mechanism for dihydropyridine binding to L-type Ca(2+)-channels as revealed by fluorescence resonance energy transfer. <i>Biochemistry</i> , 1994 , 33, 11875-83	3.2	35
22	Purification and reconstitution of skeletal muscle calcium channels. <i>Methods in Enzymology</i> , 1992 , 207, 529-46	1.7	19
21	Receptor sites for Ca2+ channel antagonists. <i>Trends in Pharmacological Sciences</i> , 1992 , 13, 256-62	13.2	342
20	Calcium channels from Cyprinus carpio skeletal muscle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 727-31	11.5	63

19	A rapid procedure for the purification of cardiac 1,4-dihydropyridine receptors from porcine heart. <i>European Journal of Pharmacology</i> , 1991 , 207, 51-9		37
18	Identification of 1,4-dihydropyridine binding regions within the alpha 1 subunit of skeletal muscle Ca2+ channels by photoaffinity labeling with diazipine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 9203-7	11.5	135
17	Very high affinity interaction of DPI 201-106 and BDF 8784 enantiomers with the phenylalkylamine-sensitive Ca2(+)-channel in Drosophila head membranes. <i>British Journal of Pharmacology</i> , 1991 , 102, 446-52	8.6	10
16	Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the alpha 1 subunit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 10769-73	11.5	137
15	Purification of L-Type Calcium Channel Drug Receptors. <i>Methods in Neurosciences</i> , 1991 , 4, 210-229		13
14	Molecular properties of calcium channels. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 1990 , 114, 1-105	2.9	160
13	Identification of a phenylalkylamine binding region within the alpha 1 subunit of skeletal muscle Ca2+ channels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 9108-12	11.5	153
12	Native and detergent-solubilized membrane extracts from Drosophila heads contain binding sites for phenylalkylamine calcium channel blockers. <i>Insect Biochemistry</i> , 1989 , 19, 309-322		22
11	Evidence for a distinct Ca2+ antagonist receptor for the novel benzothiazinone compound HOE 166. <i>Naunyn-Schmiedebergls Archives of Pharmacology</i> , 1988 , 337, 331-40	3.4	27
10	Purification and reconstitution of calcium channel drug-receptor sites. <i>Annals of the New York Academy of Sciences</i> , 1988 , 522, 150-61	6.5	11
9	Calcium channels. Vitamins and Hormones, 1988, 44, 155-328	2.5	83
8	Purified skeletal muscle 1,4-dihydropyridine receptor forms phosphorylation-dependent oligomeric calcium channels in planar bilayers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 4290-4	11.5	98
7	Resolving the structure of the Ca2+ channel by photoaffinity labelling. <i>Trends in Pharmacological Sciences</i> , 1987 , 8, 95-100	13.2	57
6	Photoaffinity labelling of the phenylalkylamine receptor of the skeletal muscle transverse-tubule calcium channel. <i>FEBS Letters</i> , 1987 , 212, 247-53	3.8	105
5	Neurotoxic aminoglycoside antibiotics are potent inhibitors of [125I]-Omega-Conotoxin GVIA binding to guinea-pig cerebral cortex membranes. <i>Naunyn-Schmiedebergls Archives of Pharmacology</i> , 1987 , 336, 583-6	3.4	67
4	Stereoselective photoaffinity labelling of the purified 1,4-dihydropyridine receptor of the voltage-dependent calcium channel. <i>FEBS Journal</i> , 1986 , 161, 603-9		82
3	Purified calcium channels have three allosterically coupled drug receptors. FEBS Letters, 1986, 197, 204-	·308	63
2	Human red-blood-cell Ca2+-antagonist binding sites. Evidence for an unusual receptor coupled to the nucleoside transporter. <i>FEBS Journal</i> , 1985 , 150, 67-77		64

Ca2+ antagonist receptor sites on human red blood cell membranes. *European Journal of Pharmacology*, **1985**, 108, 329-30

5.3 20